Clinical Impacts of Donor Types of Living vs. Deceased Donors: Predictors of One-Year Mortality in Patients with Liver Transplantation.
10.3346/jkms.2017.32.8.1258
- Author:
Eun Jung KIM
1
;
Seungjin LIM
;
Chong Woo CHU
;
Je Ho RYU
;
Kwangho YANG
;
Young Mok PARK
;
Byung Hyun CHOI
;
Tae Beom LEE
;
Su Jin LEE
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea. beauty192@hanmail.net
- Publication Type:Original Article
- Keywords:
Liver Transplantation;
Mortality;
Living Donor;
BNP;
Infection
- MeSH:
Asian Continental Ancestry Group;
Busan;
Carcinoma, Hepatocellular;
Donor Selection;
Follow-Up Studies;
Gyeongsangnam-do;
Hemorrhage;
Humans;
Intensive Care Units;
Liver Diseases;
Liver Transplantation*;
Liver*;
Living Donors;
Mortality*;
Natriuretic Peptide, Brain;
Tissue Donors*;
Transplant Recipients;
Ventilators, Mechanical
- From:Journal of Korean Medical Science
2017;32(8):1258-1262
- CountryRepublic of Korea
- Language:English
-
Abstract:
Transplantation studies about the clinical differences according to the type of donors are mostly conducted in western countries with rare reports from Asians. The aims of this study were to evaluate the clinical impacts of the type of donor, and the predictors of 1-year mortality in patients who underwent liver transplantation (LT). This study was performed for liver transplant recipients between May 2010 and December 2014 at the Pusan National University Yangsan Hospital. A total of 185 recipients who underwent LT were analyzed. Of the 185 recipients, 109 (58.9%) belonged to the living donor liver transplantation (LDLT) group. The median age was 52.4 years. LDLT recipients had lower model for end-stage liver disease (MELD) score compared with better liver function than deceased donor liver transplantation (DDLT) recipients (mean ± standard deviation [SD], 12.5 ± 8.3 vs. 24.9 ± 11.7, respectively; P < 0.001), and had more advanced hepatocellular carcinoma (HCC) (62.4% vs. 21.1%, respectively; P = 0.001). In complications and clinical outcomes, LDLT recipients showed shorter stay in intensive care unit (ICU) (mean ± SD, 10.8 ± 8.8 vs. 23.0 ± 13.8 days, respectively, P < 0.001), ventilator care days, and post-operative admission days, and lower 1-year mortality (11% vs. 27.6%, respectively, P = 0.004). Bleeding and infectious complications were less in LDLT recipients. Recipients with DDLT (P = 0.004) showed higher mortality in univariate analysis, and multi-logistic regression analysis found higher MELD score and higher pre-operative serum brain natriuretic peptide (BNP) were associated with 1-year mortality. This study may guide improved management before and after LT from donor selection to post-operation follow up.
